Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey

COVID-19 Clinical Trial

Official title:

A Phase IIb Randomized Double-Blinded Positive Controlled Trial to Evaluate the Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults Who Have Completed Two Doses of CoronaVac® or the mRNA Vaccine (Comirnaty) in Turkey

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT05150496
• Other study ID #: PRO-nCOV-2002
• Status: Suspended
• Phase: Phase 2
• Start date: December 15, 2022
• Est. completion date: January 15, 2023

Study information

• Verified date: November 2021
• Source: Sinovac Biotech Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blinded, and positive-controlled Phase IIb clinical trial of COVID-19 vaccine (CoronaVac®) manufactured by Sinovac Research & Development Co., Ltd.The purpose of this study is to evaluate the immunogenicity of using the high (1200SU) or medium (600SU) dose of CoronaVac® as the booster dose.

Description:

This is a randomized, double-blinded, and positive-controlled phaseⅡb clinical trial of 640 participants aged 18 years and above, who have completed 2 doses of inactivated COVID-19 vaccine (CoronaVac®) or mRNA COVID-19 vaccine (Comirnaty) as the primary vaccination. Participants will be enrolled and randomly assigned into two arms at a ratio of 1:1 to receive a booster dose of medium-dose (600SU) or high-dose (1200SU) COVID-19 Vaccine. For those who were vaccinated with CoronaVac®, the booster dose will be given 3-8 months after their second dose. For those who were vaccinated with Comirnaty, the booster dose will be given 6-8 months after their second dose. Each participant will be collected 5.0 ml blood sample before vaccination and 14 days,3 months and 6 months after booster immunization.Immunogenicity assessments will be determined by neutralizing antibodies in all participants.In addition,all participants will be monitored for immediate reactions (within 30 minutes) after the booster dose vaccination, adverse events of special interest (AESIs) and serious adverse events (SAEs) for 12 months after booster dose inoculation. In addition, all participants in will be monitored for local and systemic solicited adverse events (AEs) within 7 days and the unsolicited AEs within 28 days.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 640
• Est. completion date: January 15, 2023
• Est. primary completion date: January 15, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Healthy adults aged 18 years and above, who have received 2 prior doses of inactivated COVID-19 vaccine (CoronaVac®) or mRNA COVID-19 vaccine (Comirnaty), with the second dose given 3-8 months (for CoronaVac® recipients) and 6-8 months (for Comirnaty recipients) prior to the day of booster vaccination in the present study;
• Antigen rapid testing negative at the day of enrollment on site or with a PCR negative result within 72 hours before enrollment;
• The participants are able to understand and sign the informed consent voluntarily;
• Female participants who have a negative pregnancy test on the day of vaccination, and not currently breastfeeding;
• The participants are planning to be living in Turkey for the following 1 year after attending this study;
• The participants must be willing to provide verifiable identification (in accordance with the local regulations), has means to be contacted and to contact the investigator during the study.

Exclusion Criteria:

• History of confirmed or currently with the infection of SARS-CoV-2 prior to randomization;
• Any prior administration of another investigational coronavirus vaccine or current/planned simultaneous participation in another interventional study to prevent or treat COVID-19;
• Known allergy to vaccines or vaccine ingredients, and serious adverse reactions to vaccines, such as urticaria, dyspnea, angioneurotic edema;
• Serious chronic disease, serious cardiovascular disease, hypertension and diabetes that cannot be controlled by drugs, hepatorenal disease, malignant tumor, etc;
• Acute central nervous system diseases such as encephalitis/myelitis, acute disseminating encephalomyelitis, and related disorders;
• Receipt of blood/plasma products or immunoglobulins in the past 3 months before vaccination in this study;
• Participation in other studies involving study intervention within 30 days prior to vaccination in this study;
• Receipt of attenuated live vaccines in the past 14 days prior to vaccination in this study;
• Receipt of inactivated or subunit vaccines in the past 7 days prior to vaccination in this study;
• Acute exacerbation or presentation of stable chronic diseases (including but not limited to asthma, migraine, gastrointestinal disorder, etc.);
• Acute febrile illness with axillary temperature >37.5°C on the day of vaccination; enrollment could be considered if the fever is absent for 72 hours prior to vaccination;
• According to the investigator's judgment, the participant has any other factors that might interfere with the results of the clinical trial or pose additional risk to the participant due to participation in the study.

Related Conditions & MeSH terms

• COVID-19

Intervention

Biological:
• Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated
Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
• High-dose COVID-19 Vaccine(Vero Cell),Inactivated
High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection

Locations

Country	Name	City	State
Turkey	Hacettepe University Faculty of Medicine, Department of Internal Diseases / Infectious Diseases and Clinical Microbiology Unit	Ankara
Turkey	Republic of Turkey Ministry of Health Ankara City Hospital Department of Internal Diseases	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Sinovac Research and Development Co., Ltd.

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Immunogenicity index-The seropositivity rate of neutralizing antibodies	The seropositivity rate of neutralizing antibodies before vaccination, 14 days (14-28 days) , 3-month (±2 weeks), and 6-month (±2 weeks) after the booster dose vaccination	Before vaccination, 14 days (14-28 days) , 3-month (±2 weeks), and 6-month (±2 weeks) after the booster dose vaccination
Other	Immunogenicity index-GMT of neutralizing antibodies	GMT of neutralizing antibodies before vaccination, 14 days (14-28 days) , 3-month (±2 weeks), and 6-month (±2 weeks) after the booster dose vaccination	Before vaccination, 14 days (14-28 days) , 3-month (±2 weeks), and 6-month (±2 weeks) after the booster dose vaccination
Other	Immunogenicity index-GMI of neutralizing antibodies	GMI of neutralizing antibodies before vaccination, 14 days (14-28 days) , 3-month (±2 weeks), and 6-month (±2 weeks) after the booster dose vaccination	Before vaccination, 14 days (14-28 days) , 3-month (±2 weeks), and 6-month (±2 weeks) after the booster dose vaccination
Primary	Immunogenicity index-GMT of neutralizing antibodies	GMT of neutralizing antibodies on 14 days (14-28 days) after the booster dose vaccination	14 days (14-28 days) after the booster dose vaccination
Secondary	Immunogenicity index-Seropositivity rate of neutralizing antibodies	Seropositivity rate of neutralizing antibodies on 14 days (14-28 days) after the booster dose vaccination	14 days (14-28 days) after the booster dose vaccination
Secondary	Immunogenicity index-GMI of neutralizing antibodies	GMI of neutralizing antibodies on 14 days (14-28 days) after the booster dose vaccination	14 days (14-28 days) after the booster dose vaccination
Secondary	Immunogenicity index-The seropositivity rate of neutralizing antibody	Seropositivity rate of neutralizing antibody at 3 (±2 weeks) and 6 (±2 weeks) months after the booster dose vaccination	At 3 (±2 weeks) and 6 (±2 weeks) months after the booster dose vaccination
Secondary	Immunogenicity index-GMT of neutralizing antibody	GMT of neutralizing antibody at 3 (±2 weeks) and 6 (±2 weeks) months after the booster dose vaccination	At 3 (±2 weeks) and 6 (±2 weeks) months after the booster dose vaccination
Secondary	Safety index-Occurrence, intensity, duration, and relationship of solicited local and systemic AEs	Occurrence, intensity, duration, and relationship of solicited local and systemic AEs for 7 days following the booster dose vaccination	7 days following the booster dose vaccination
Secondary	Safety index-Occurrence, intensity, duration, and relationship of unsolicited AEs	Occurrence, intensity, duration, and relationship of unsolicited AEs for 28 days post booster vaccination	28 days post booster vaccination
Secondary	Safety index-Occurrence and relationship of SAEs	Occurrence and relationship of SAEs (from the booster dose to 12 months post booster vaccination)	From the booster dose to 12 months post booster vaccination
Secondary	Safety index-Occurrence and relationship of AESI	Occurrence and relationship of AESI (from the booster dose to 12 months post booster vaccination)	From the booster dose to 12 months post booster vaccination